Peijia Medical Limited (HKG:9996)

Market Cap	2.59B -36.5%
Revenue (ttm)	905.10M +17.4%
Net Income	-162.77M
EPS	-0.24
Shares Out	672.63M
PE Ratio	n/a
Forward PE	264.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,589,000
Open	4.120
Previous Close	4.150
Day's Range	3.850 - 4.200
52-Week Range	3.730 - 7.370
Beta	0.61
Analysts	Strong Buy
Price Target	9.82 (+155.07%)
Est. Earnings	Nov 20, 2026

About Peijia Medical

Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People’s Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company's products include transcatheter aortic valve replacement (TAVR) systems, crosslinked dry-tissue and polymeric tri leaflet TAVR systems, transcatheter aortic valve s...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2012
• Employees: 1,033
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9996

Financial Performance

In 2025, Peijia Medical's revenue was 712.87 million, an increase of 15.82% compared to the previous year's 615.48 million. Losses were -203.29 million, -10.28% less than in 2024.

Financial numbers in CNY

Analyst Summary

According to 4 analysts, the average rating for 9996 stock is "Strong Buy." The 12-month stock price target is $9.82, which is an increase of 155.07% from the latest price.

Price Target

$9.82

(155.07% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error